Clinical Trials

Clinical trials are designed to assess the efficacy of pharmacologic compounds. These are usually double-blind, placebo- controlled treatment trials, link to terms though more rarely open-labeled studies are performed. Most recently, these trials use an adjunctive medication approach where the study medication is added to the patient’s current pharmacologic regimen. 

The research goals involve the investigation of novel treatments for residual positive and negative symptoms and cognitive impairments. In addition, pharmacologic strategies are being evaluated to address health related co-morbidities such as nicotine addiction, metabolic abnormalities and weight gain. 

Novel Treatments

Novel treatments are investigated in the ORP to find better pharmacological agents for the treatment of negative and positive symptoms and cognitive impairments. Current agents being investigated include atomoxetine for the study of cognitive impairments, and the use of adjunctive risperidone in the treatment of clozapine partial responders. Recently, protocols have been completed which investigated the use of galantamine for cognitive impairments and the use of glutamaterigic agents for cognive impairments and negative symptoms. In the near future, other investigational agents will be studied for their cognitive enhancing effects.

Health

Non-Medical Clinical Trials

This site will work and look much better in a modern web browser, such as Internet Explorer 6, Firefox, or Safari 1.2 (Mac)
Copyright © University of Maryland School of Medicine